FMP

FMP

Enter

Jefferies Downgrades Moderna Inc. (NASDAQ:MRNA) to Hold

-

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

  • Jefferies has downgraded Moderna Inc. (NASDAQ:MRNA) from Buy to Hold, indicating a shift in their outlook towards the biotech company.
  • Despite the broader stock market's positive momentum, Moderna's shares declined by -12.36% following the announcement of reduced R&D spending.
  • The stock market saw overall gains, with the S&P 500 up by 0.8%, driven by a decrease in wholesale inflation and anticipation of favorable Federal Reserve interest rate decisions.

On September 12, 2024, Jefferies adjusted its stance on Moderna Inc. (NASDAQ:MRNA), moving its rating to Hold from Buy. This decision by Jefferies signals a shift in their perspective towards the biotechnology company, known for its pioneering mRNA technology and COVID-19 vaccine. Moderna's stock price at the time of this downgrade was $69.68, as reported by TheFly. This change in rating is significant as it reflects analysts' reassessment of the company's future growth prospects and valuation.

The broader stock market, including the S&P 500, showed positive momentum on the same day, with a 0.8% increase, marking its fourth consecutive day of gains. This uptrend in the market was largely driven by a decrease in wholesale inflation for August, as indicated by the latest Producer Price Index (PPI) report. Such economic indicators are crucial as they influence the Federal Reserve's decisions on interest rates, which in turn affect stock market performance.

Despite the overall market's positive trajectory, Moderna's shares took a hit, declining by $9.83 or -12.36%, to close at $69.68. This drop was notably sharp against the backdrop of the market's gains and was primarily attributed to the company's announcement of a reduction in its research and development (R&D) spending. This move by Moderna diverged from the broader market optimism, highlighting the company-specific challenges it faces, including the need to manage its R&D expenses effectively.

The stock market's performance on this day also saw other notable movements, such as Warner Bros. Discovery's shares jumping by 10% following a renewed distribution deal, and Kroger's stock rising due to positive earnings news. Meanwhile, the Nasdaq and the Dow also experienced gains, reflecting a general investor optimism fueled by cooling inflation and anticipation of a favorable interest rate decision by the Federal Reserve.

Moderna's stock price movement, from a high of $70.85 to a low of $64.11 during the trading day, and its year-to-date fluctuation between $170.47 and $62.55, underscore the volatility and the challenges the company faces. With a market capitalization of approximately $26.78 billion and a trading volume of about 23.95 million shares, Moderna remains a significant player in the biotech industry. However, its recent decision to cut R&D spending and the subsequent stock price decline reflect the complex dynamics at play, including investor reactions to company strategies and broader market trends.

Other Blogs

May 14, 2024 11:41 AM - Sanzhi Kobzhan

The easiest way to calculate stock’s target price and why the target price is important.

A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...

blog post title

May 16, 2024 8:06 PM - Gordon Thompson

Deutsche Bank Upgrades AST SpaceMobile to Buy Amid Legal Challenges

On Thursday, May 16, 2024, Deutsche Bank upgraded its rating on NASDAQ:ASTS to Buy, maintaining a hold position. At the time of the announcement, ASTS was trading at $4.03. This decision was accompanied by an increase in the price target for AST SpaceMobile, raised to $22 from $19, as detailed in a ...

blog post title

May 24, 2024 9:30 AM - Rajnish Katharotiya

How to Access and Analyze Earnings Call Transcripts

Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep